A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

April 10, 2024

Primary Completion Date

February 5, 2025

Study Completion Date

March 31, 2026

Conditions
Breast Cancer
Interventions
DRUG

BB-1701

BB-1701 will be administered as an intravenous infusion, every 3 weeks (21-day cycle).

Trial Locations (49)

10065

Memorial Sloan-Kettering Cancer Center, New York

32804

AdventHealth Cancer Institute - Orlando, Orlando

44111

Cleveland Clinic - Fairview Hospital - Cancer Center (Moll Cancer Center), Cleveland

44124

Cleveland Clinic - Hillcrest Hospital - Hillcrest Cancer Center, Cleveland

46227

Community Cancer Center South, Indianapolis

48604

Fort Wayne Medical Oncology & Hematology, Fort Wayne

50309

Mission Blood and Cancer, Des Moines

57105

Avera Cancer Institute, Sioux Falls

68506

NHO Revive Research Institute LLC, Lincoln

87109

New Mexico Oncology Hematology Consultants, Albuquerque

90095

UCLA Center for East-West Medicine, Los Angeles

90720

Cancer and Blood Specialty Clinic, Los Alamitos

97301

Oregon Oncology Specialists, Salem

94143-2208

UCSF, San Francisco

06510

Yale New Haven Hospital, New Haven

33612-9416

Moffitt Cancer Center, Tampa

48109-5000

University of Michigan Hospital, Ann Arbor

63110-1032

Washington University in St. Louis School of Medicine, St Louis

68130-2042

Nebraska Cancer Specialist, Omaha

08816

Astera Cancer Care, East Brunswick

07932-1049

Summit Medical Group, Florham Park

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

44195-0001

Cleveland Clinic, Cleveland

15213-3108

UPMC CancerCenter at Magee - Womens Hospital, Pittsburgh

29607-5253

St. Francis Cancer Center, Greenville

38138-1762

The West Clinic, PLLC dba West Cancer Cente, Germantown

98373-1428

Northwest Medical Specialties, Puyallup

Unknown

CHU Besançon - Hôpital Jean Minjoz, Besançon

Institut Régional du Cancer de Montpellier, Montpellier

Centre Armoricain de Radiotherapie Imagerie & Oncologie (CARIO), Plérin

Institut de Cancerologie de Ouest (ICO) - Saint-Herblain, Saint-Herblain

Nagoya University Hospital, Nagoya

Hiroshima City Hiroshima Citizens Hospital, Hiroshima

Hokkaido University Hospital, Sapporo

Hyogo Medical University Hospital, Nishinomiya-shi

Sagara Hospital, Social Medical Corporation Hakuaikai, Kagoshima

Kanagawa Cancer Center, Yokohama

National Cancer Center Hospital (NCCH), Chūōku

Kyoto University Hospital, Sakyo-ku

Tohoku University Hospital, Sendai

Okayama University Hospital, Okayama

Saitama Medical University International Medical Center, Hidaka-shi

Saitama Cancer Center, Kitaadachi-gun

St. Luke's International Hospital, Chuou-ku

The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto Ku

Showa University, Shinagawa Ku

Hospital Universitario Vall d'Hebron, Barcelona

HM Universitario Sanchinarro, Madrid

Hospital Beata María Ana, Madrid

All Listed Sponsors
collaborator

Bliss Biopharmaceutical (Hangzhou) Co., Ltd

INDUSTRY

lead

Eisai Inc.

INDUSTRY

NCT06188559 - A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter